Oncternal Therapeutics' Series A - II Round

Oncternal Therapeutics raised a round of funding on August 07, 2015. Investors include Hale BioPharma Ventures.

Oncternal Therapeutics, formerly Tokalas, is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers by focusing on targets that are uniquely e…

Articles about Oncternal Therapeutics' Series A - II Round: